Drug Type Antibody drug conjugate (ADC) |
Synonyms BR96-Doxorubicin, cBR96-Doxorubicin Immunoconjugate, BMS-182248 + [5] |
Target |
Action inhibitors |
Mechanism Lewis-Y antigen inhibitors(Lewis-Y antigen inhibitors), Top II inhibitors(Topoisomerase II inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | Phase 2 | United States | 15 Jan 2003 | |
Recurrent Non-Small Cell Lung Cancer | Phase 2 | United States | 15 Jan 2003 | |
Breast cancer recurrent | Phase 2 | United States | 01 Oct 2000 | |
Castration-Resistant Prostatic Cancer | Phase 2 | United States | 01 Oct 2000 | |
Colorectal Cancer | Phase 2 | United States | - | - |
Colorectal Cancer | Phase 2 | - | - | |
Colorectal Cancer | Phase 2 | - | - | |
Non-Small Cell Lung Cancer | Phase 2 | - | - | |
Prostatic Cancer | Phase 2 | - | - |
Phase 2 | metastatic non-small cell lung cancer Third line | 62 | qbubwbjxne(hwlhqbfctc) = aojqxygtmn dgawvjvwsi (oaxzxoxzdp ) | - | 15 Jul 2004 | ||
qbubwbjxne(hwlhqbfctc) = aqzzczqmml dgawvjvwsi (oaxzxoxzdp ) |